|View printer-friendly version|
Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
World Thrombosis Day, observed on
“VTE is preventable with the proper prevention and treatment procedures. We are committed to our partnership with World Thrombosis Day and ISTH to raise awareness to help reduce death and disability caused by this condition,” said
Venous thromboembolism (VTE), also known as a blood clot, is a leading cause of death and disability worldwide. Patients hospitalized for serious, common medical conditions (i.e., acutely ill medical patients) are at increased risk for VTE. In the G7 countries, an estimated 24 million acutely ill medical patients are hospitalized each year and are at risk of VTE, either while in the hospital or following discharge. More than one million VTE events and 150,000 VTE-related deaths occur annually in acutely ill medical patients in the G7 countries, despite the standard use of injectable enoxaparin and other heparins in the hospital. More than half of VTE events occur after patients are discharged from the hospital.
“Our partners are critical in helping to expand the reach of World Thrombosis Day and we are proud to partner with Portola for the third straight year,” said
Recent advances in the field of thrombosis have led to the development of novel oral anticoagulants (NOACs) to prevent and treat VTEs. NOACs are predominantly comprised of a class of drugs called Factor Xa inhibitors, which are indicated to prevent stroke and blood clots in people with atrial ﬁbrillation; to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE); and to prevent DVT, which may lead to PE, following hip or knee replacement surgery. In
About World Thrombosis Day
Launched in 2014 and held annually on
About the ISTH
Founded in 1969, the
About Portola Pharmaceuticals, Inc. ®
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, cerdulatinib’s potential as a treatment for hematologic cancers and the potential of Portola’s other product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: failure to obtain FDA and/or EMA approval for one or more of our product candidates, regulatory developments in the United States and foreign countries; our expectation that we will incur losses for the foreseeable future and will need additional funds to finance our operations; the accuracy of our estimates regarding our ability to initiate and/or complete our clinical trials and the timing and expense of these trials; the results of our clinical trials related to the efficacy and safety of our product candidates; our potential inability to manufacture our product candidates on a commercial scale in a timely or cost-efficient manner; the accuracy of our estimates regarding expenses and capital requirements; our ability to successfully build a hospital-based sales force and commercial infrastructure; our ability to obtain and maintain intellectual property protection for our product candidates; and our ability to retain key scientific or management personnel. These and other risks and uncertainties are described more fully in our most recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.